About Us
Overview
Leadership Team
Board of Directors
Scientific Co-Founders
Scientific Advisory Board
Our Technology
Overview
Autologous Approach
Allogeneic Approach
Pipeline
Overview
LGMD2A
FSHD
Clinical Trials
Newsroom
Top News
Publications
In the News
Media Inquiries
Careers
Get in touch
Top News
July 18, 2023
Vita Therapeutics Collaborates with MilliporeSigma to Advance Preclinical Program for Vita’s Preclinical Cell Therapy for Limb-Girdle Muscular Dystrophy (LGMD2A)
Press Release
October 12, 2022
Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers
Press Release
March 22, 2022
Vita Therapeutics Bolsters Leadership to Advance Multiple Technology Platforms
Press Release
July 23, 2021
Vita Therapeutics receives Orphan Drug Designation from FDA for new novel treatment
Press Release
Terms and Conditions
Privacy Policy
Cookies
Social Media
© 2023 Vita Therapeutics, Inc. All rights reserved
